A phase II trial of cabozantinib (CABO) for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting
| Autor: | Christian Michael Squillante, Zakkiyya A Posey, Raven Klein Yurtal, Dena M. Torrente, Carolyn Grande, Mark Yarchoan, Andrea B. Troxel, Sangeeta Shenoy, Nikhil Bhat, Anne Kathleen Harlacker, Marcia S. Brose |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Cancer Research
Cabozantinib biology Kinase business.industry First line VEGF receptors 030209 endocrinology & metabolism Phase i study Thyroid carcinoma 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Oncology chemistry Refractory hemic and lymphatic diseases 030220 oncology & carcinogenesis Cancer research biology.protein Medicine business |
| Zdroj: | Journal of Clinical Oncology. 36:6088-6088 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2018.36.15_suppl.6088 |
| Popis: | 6088Background: CABO is a multi-tyrosine kinase inhibitor targeting VEGF receptor kinase, RET, MET and AXL. We previously participated in a Phase I study which suggested activity in the RAI-refract... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|